|
 |
| home > epc > winter 2001 > the trojan horse of oncology - the role of stealth drug delivery |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
The word 'cancer' instils fear into most people. One in four people will develop cancer at some point in their life and, given the dismal cure rates for most common cancers, many of those who are diagnosed with some form of the disease will eventually die of it. Fear is often augmented by the knowledge that the relentlessly growing cancer often brings with it pain, suffering and debility.
Far from being 'mindless' automatons, it has been shown that tumour cells employ numerous strategies to promote growth. Complicated mechanisms to switch on growth; vascular endothelial growth factors (VEGF) to create a blood supply as a pipeline to bring nutrients; and pumps such as p-Glycoprotein to get rid of ingested cellular toxins are some of the strategies that have evolved.
While the fight against cancer begins with prevention, once it has developed, permanent eradication of the disease requires all the skills oncologists can muster to outwit the tumour cell and the mechanisms it employs to ensure its continued cellular survival and tumour growth.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Ultra slim and ultra quick
More info >>
|
|
 |
